|Articles|March 23, 2021
GxP regulated industry assessments of SoftMax Pro Software
Author(s)Molecular Devices
This document outlines references to 21 CFR Part 11 and EudraLex Annex 11 and how they apply to the implementation of SoftMax Pro GxP Data Acquisition and Analysis Software in regulated environments.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
2
How Biopharma Navigates the 2026 Economic Shift
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5